Advertisement

Topics

Hardman & Co Research: Oxford BioMedica (OXB): Gene-therapy for Parkinson's: clinical progression

05:21 EDT 14 Jun 2018 | FinanzNachrichten

Dow Jones received a payment from EQS/DGAP to publish this press release. Hardman & Co Research Hardman & Co Research: Oxford BioMedica (OXB): Gene-therapy for Parkinson's: clinical progression 14...

Original Article: Hardman & Co Research: Oxford BioMedica (OXB): Gene-therapy for Parkinson's: clinical progression

NEXT ARTICLE

More From BioPortfolio on "Hardman & Co Research: Oxford BioMedica (OXB): Gene-therapy for Parkinson's: clinical progression"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...